HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Non-IgE mediated allergic asthma — Clinical Guidelines

Overview

Non-IgE mediated allergic asthma, also known as non-atopic asthma, represents a subset of asthma where symptoms arise from mechanisms independent of immunoglobulin E (IgE) antibodies. This form of asthma can mimic classic atopic asthma clinically but lacks the hallmark IgE-mediated responses seen in allergic triggers. It affects individuals who may not have a typical atopic background, making diagnosis and management challenging. Understanding and recognizing this condition is crucial for tailoring appropriate treatment strategies and improving patient outcomes in day-to-day practice 17.

Pathophysiology

The pathophysiology of non-IgE mediated allergic asthma involves complex interactions beyond the traditional IgE-mediated pathways. Key mechanisms include dysregulation of innate immune responses, such as activation of mast cells and basophils through non-IgE pathways. These cells can be triggered by various stimuli like nonsteroidal anti-inflammatory drugs (NSAIDs), environmental irritants, and other inflammatory mediators such as prostaglandins and leukotrienes. For instance, NSAIDs can induce hypersensitivity reactions through mechanisms involving cyclooxygenase inhibition and subsequent arachidonic acid metabolism, leading to the release of pro-inflammatory mediators like prostaglandins and leukotrienes 17 18. Additionally, bradykinin and endothelin-1 may play roles in bronchoconstriction and inflammation, contributing to airway hyperresponsiveness and inflammation in these patients 10 13.

Epidemiology

The exact incidence and prevalence of non-IgE mediated allergic asthma are less well-defined compared to IgE-mediated asthma due to diagnostic challenges and variability in reporting. However, it is recognized that this condition can affect individuals across all age groups, with no significant sex predilection noted in most studies. Geographic and environmental factors may influence susceptibility, with higher exposure to certain irritants or pollutants potentially increasing risk. Trends suggest an increasing awareness and recognition of non-IgE mediated asthma, possibly due to improved diagnostic tools and a broader understanding of asthma subtypes 17.

Clinical Presentation

Patients with non-IgE mediated allergic asthma often present with typical asthma symptoms such as wheezing, shortness of breath, chest tightness, and cough. However, atypical presentations can include exacerbations triggered by NSAIDs or other non-allergic stimuli, which may not align with typical atopic triggers. Red-flag features include severe, unpredictable exacerbations, particularly following exposure to NSAIDs or other specific triggers, and lack of response to standard inhaled corticosteroids. These presentations necessitate a thorough diagnostic workup to differentiate from other respiratory conditions 17.

Diagnosis

The diagnosis of non-IgE mediated allergic asthma involves a comprehensive approach that includes clinical history, physical examination, and specific diagnostic tests. Key steps include:

Detailed History: Focus on triggers, particularly non-allergic factors like NSAID exposure, and response to treatment.

Physical Examination: Assess for signs of respiratory distress, wheezing, and other systemic manifestations.

Specific Tests:

- Basophil Activation Test (BAT): Evaluates basophil activation in response to specific triggers, useful in identifying non-IgE mediated reactions 3. - Drug Provocation Tests: For suspected NSAID hypersensitivity, carefully controlled drug provocation tests may be necessary 3. - Skin Tests: While less specific for non-IgE mediated asthma, skin tests can help rule out other allergic conditions 7. - Pulmonary Function Tests (PFTs): Spirometry to assess airflow obstruction and reversibility. - Blood Tests: Assess for markers of inflammation and exclude other conditions (e.g., eosinophilia).

Differential Diagnosis:

Chronic Obstructive Pulmonary Disease (COPD): Typically associated with smoking history and airflow limitation without significant reversibility.

Heart Failure: Wheezing and dyspnea can mimic asthma but are often accompanied by peripheral edema and jugular venous distension.

Gastroesophageal Reflux Disease (GERD): Can exacerbate asthma symptoms but lacks specific respiratory findings.

Management

First-Line Treatment

Controller Medications:

- Inhaled Corticosteroids: Fluticasone 100-250 mcg bid or Budesonide 800-1600 mcg/day 1. - Long-Acting Beta-Agonists (LABAs): Salmeterol 50 mcg bid or Formoterol 9-18 mcg bid, when combined with inhaled corticosteroids 1.

Anticholinergics: Ipratropium 180-360 mcg tid or Tiotropium 18 mcg qd 10.

Second-Line Treatment

Leukotriene Receptor Antagonists (LTRAs): Montelukast 10 mg qhs 12.

Mast Cell Stabilizers: Cromolyn sodium 200 mcg qid via nebulizer 16.

Refractory Cases / Specialist Referral

Omalizumab: For severe cases with documented IgE sensitization, though primarily indicated for IgE-mediated asthma, consider in consultation 4.

Immunotherapy: For specific triggers like NSAIDs, consult allergist for tailored protocols 3.

Bronchial Thermoplasty: In severe, refractory cases, consider in specialized centers 1.

Monitoring: Regular PFTs, symptom diaries, and adjust medications based on clinical response and exacerbation frequency 1.

Complications

Acute Exacerbations: Triggered by non-allergic factors like NSAIDs, requiring prompt intervention with bronchodilators and systemic corticosteroids.

Chronic Inflammation: Persistent airway inflammation can lead to irreversible airflow limitation if not adequately managed.

Cardiovascular Complications: Exacerbations may precipitate arrhythmias or exacerbate underlying heart conditions 13.

Prognosis & Follow-up

The prognosis for non-IgE mediated allergic asthma varies widely depending on the severity and responsiveness to treatment. Prognostic indicators include the frequency of exacerbations, response to controller medications, and control of identified triggers. Recommended follow-up intervals typically include:

Monthly during initial stabilization.

Quarterly for stable patients.

Bi-monthly to monthly if exacerbations occur or treatment adjustments are needed.

Lung function tests every 6-12 months to monitor for changes in airway obstruction 1.

Special Populations

Pediatrics: Diagnosis can be challenging due to overlapping symptoms with viral respiratory infections. Careful monitoring and avoidance of potential triggers are crucial 17.

Elderly: Increased risk of comorbidities like heart disease and GERD, necessitating a holistic approach to management 13.

NSAID Intolerance: Specific attention to dietary and medication triggers, possibly requiring alternative pain management strategies 17.

Key Recommendations

Comprehensive Clinical History: Include detailed exposure history to non-allergic triggers like NSAIDs 17 (Evidence: Strong).

Utilize Basophil Activation Test (BAT) for suspected non-IgE mediated reactions 3 (Evidence: Moderate).

Inhaled Corticosteroids as first-line controller therapy 1 (Evidence: Strong).

Avoidance of Triggers: Implement strict avoidance strategies for identified non-allergic triggers 17 (Evidence: Moderate).

Regular Monitoring: Perform pulmonary function tests every 6-12 months to assess disease progression 1 (Evidence: Moderate).

Consider LTRAs for Refractory Cases when inhaled corticosteroids and LABAs are insufficient 12 (Evidence: Moderate).

Specialist Referral for Refractory Cases involving allergists or pulmonologists for advanced management options 1 (Evidence: Expert opinion).

Tailored Immunotherapy in consultation with allergists for specific trigger avoidance 3 (Evidence: Moderate).

Monitor for Complications including cardiovascular effects during exacerbations 13 (Evidence: Moderate).

Personalized Follow-Up Schedules based on patient stability and exacerbation frequency 1 (Evidence: Expert opinion).

References

1 Steiner M, Harrer A, Lang R, Schneider M, Ferreira T, Hawranek T et al.. Basophil activation test for investigation of IgE-mediated mechanisms in drug hypersensitivity. Journal of visualized experiments : JoVE 2011. link 2 Burka JF, Saad MH. Bronchodilator-mediated relaxation of normal and ovalbumin-sensitized guinea-pig airways: lack of correlation with lung adenylate cyclase activation. British journal of pharmacology 1984. link 3 Ariza A, Fernandez TD, Doña I, Aranda A, Blanca-Lopez N, Melendez L et al.. Basophil activation after nonsteroidal anti-inflammatory drugs stimulation in patients with immediate hypersensitivity reactions to these drugs. Cytometry. Part A : the journal of the International Society for Analytical Cytology 2014. link 4 Couto M, Gaspar A, Piedade S, Arêde C, Menezes M, Sousa MJ et al.. IgE-mediated metamizol allergy and the usefulness of the cellular allergen stimulation test. European annals of allergy and clinical immunology 2012. link 5 Hertenstein A, Schumacher T, Litzenburger U, Opitz CA, Falk CS, Serafini T et al.. Suppression of human CD4+ T cell activation by 3,4-dimethoxycinnamonyl-anthranilic acid (tranilast) is mediated by CXCL9 and CXCL10. Biochemical pharmacology 2011. link 6 Lee JY, Kim CJ. Arctigenin, a phenylpropanoid dibenzylbutyrolactone lignan, inhibits type I-IV allergic inflammation and pro-inflammatory enzymes. Archives of pharmacal research 2010. link 7 Palma-Carlos AG, Medina M, Palma-Carlos ML. Skin tests in NSAIDS hypersensitivity. European annals of allergy and clinical immunology 2006. link 8 Wang LY, Unehara T, Kitanaka S. Anti-inflammatory activity of new guaiane type sesquiterpene from Wikstroemia indica. Chemical & pharmaceutical bulletin 2005. link 9 Kim MS, Na HJ, Han SW, Jin JS, Song UY, Lee EJ et al.. Forsythia fructus inhibits the mast-cell-mediated allergic inflammatory reactions. Inflammation 2003. link 10 Tramontana M, Lecci A, Meini S, Montserrat X, Pascual J, Giuliani S et al.. Differences between peptide and nonpeptide B(2) bradykinin receptor antagonists in blocking bronchoconstriction and hypotension induced by bradykinin in anesthetized Guinea pigs. The Journal of pharmacology and experimental therapeutics 2001. link 11 Asano M, Sawai H, Hatori C, Inamura N, Fujiwara T, Nakahara K. Effects of a nonpeptide bradykinin B2 receptor antagonist, FR167344, on guinea-pig tracheal smooth muscle bradykinin receptors. Canadian journal of physiology and pharmacology 1998. link 12 Ishii K, Yakuo I, Motoyoshi S, Nakagawa H, Nakamura H. Inhibition of leukotriene production by N-[4-[4-(diphenylmethyl)-1- piperazinyl]butyl]-3-(6-methyl-3-pyridyl) acrylamide (AL-3264), a new antiallergic agent. Japanese journal of pharmacology 1994. link 13 Uchida Y, Saotome M, Nomura A, Ninomiya H, Ohse H, Hirata F et al.. Endothelin-1-induced relaxation of guinea pig trachealis muscles. Journal of cardiovascular pharmacology 1991. link 14 Ohuchi K, Takahashi C, Hirasawa N, Watanabe M, Fujiki H, Tsurufuji S. Stimulation of histamine release and arachidonic acid metabolism in rat peritoneal mast cells by thapsigargin, a non-TPA-type tumor promoter. Biochimica et biophysica acta 1989. link90091-x) 15 Makino H, Naka T, Saijo T, Maki Y. Inhibitory effect of methyl 7-butyl-4,5,6,7-tetrahydro-3-methylamino-4,6-dioxo-5-propyl-2H-pyrazol o[3, 4-d]pyrimidine-2-carboxylate (AA-2379) on type III allergic (Arthus) reaction. Agents and actions 1988. link 16 Chand N, Diamantis W, Pillar J, Sofia RD. Modulation of allergic and nonallergic histamine secretion by lipoxygenase inhibitors. Research communications in chemical pathology and pharmacology 1987. link 17 Housholder GT. Intolerance to aspirin and the nonsteroidal anti-inflammatory drugs. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 1985. link90252-6) 18 Magro AM. Effect of inhibitors of arachidonic acid metabolism upon IgE and non-IgE-mediated histamine release. International journal of immunopharmacology 1982. link90004-2)

Non-IgE mediated allergic asthma